ROSG Share Price

Open 0.61 Change Price %
High 0.62 1 Day -0.01 -1.61
Low 0.61 1 Week 0.01 1.67
Close 0.61 1 Month -0.05 -7.58
Volume 43672 1 Year -0.63 -50.81
52 Week High 1.60
52 Week Low 0.55
ROSG Important Levels
Resistance 2 0.62
Resistance 1 0.62
Pivot 0.61
Support 1 0.60
Support 2 0.60
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Rosetta Genomics Ltd. (NASDAQ: ROSG)

ROSG Technical Analysis 5
As on 8th Dec 2016 ROSG Share Price closed @ 0.61 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.00 & Strong Sell for SHORT-TERM with Stoploss of 0.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
ROSG Target for December
1st Target up-side 0.77
2nd Target up-side 0.85
3rd Target up-side 0.94
1st Target down-side 0.51
2nd Target down-side 0.43
3rd Target down-side 0.34
ROSG Other Details
Segment EQ
Market Capital 42571844.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.rosettagenomics.com
ROSG Address
ROSG
10 Plaut Street
Science Park
Rehovot, 76706
Israel
Phone: 972 73 222 0700
Fax: 972 73 222 0701
ROSG Latest News
Interactive Technical Analysis Chart Rosetta Genomics Ltd. ( ROSG NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Rosetta Genomics Ltd.
ROSG Business Profile
Rosetta Genomics Ltd., is seeking to develop and commercialize diagnostic tests based on discovered group of genes known as microRNAs. The Company has established a clinical laboratory improvement amendment (CLIA)-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology. In July 2011, the Company launched its fifth product - miRview lung. As of December 31, 2011, the Company launched five tests based on its five microRNA technologies: miRview mets; miRview mets2; miRview squamous; miRview meso, and miRview lung.